Rare diseases
Investigational molecules
Locations
A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease
The NetherlandsStudy of Tumor-Infiltrating Lymphocyte Cell Therapy and Aldesleukin for Patients with Advanced Stage Ovarian Cancer as Initial Treatment
The NetherlandsStudy of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back
The NetherlandsTesting MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment
The NetherlandsA Study Testing SUL-238 in Patients with Early, Untreated Parkinson's Disease to Assess Effects on Brain Energy Metabolism
The NetherlandsTesting a Drug Combination with Fluorouracil, Irinotecan, Oxaliplatin, and Folinic Acid Plus Radiation Therapy for Patients with Advanced Rectal Cancer
The NetherlandsStudy of ONC206 for children and young adults with newly diagnosed or recurrent diffuse midline glioma and other recurrent brain tumors
The NetherlandsA Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment
The NetherlandsA Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans
The NetherlandsStudy of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia
The NetherlandsStudy of abatacept, tocilizumab, and tofacitinib compared to a second TNF inhibitor for children with juvenile idiopathic arthritis who did not respond to TNF inhibitor treatment
The NetherlandsA study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy
The NetherlandsTell us about your condition – we search every trial in Europe and connect you with the right site.
